EP1631235A4 - Compositions et methodes de modulation de l'expression de la proteine b7 - Google Patents

Compositions et methodes de modulation de l'expression de la proteine b7

Info

Publication number
EP1631235A4
EP1631235A4 EP04752823A EP04752823A EP1631235A4 EP 1631235 A4 EP1631235 A4 EP 1631235A4 EP 04752823 A EP04752823 A EP 04752823A EP 04752823 A EP04752823 A EP 04752823A EP 1631235 A4 EP1631235 A4 EP 1631235A4
Authority
EP
European Patent Office
Prior art keywords
modulation
protein
expression
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04752823A
Other languages
German (de)
English (en)
Other versions
EP1631235A2 (fr
Inventor
Frank C Bennett
Timothy A Vickers
James G Karras
Susan M Freier
Brenda F Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/444,206 external-priority patent/US20040023917A1/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP1631235A2 publication Critical patent/EP1631235A2/fr
Publication of EP1631235A4 publication Critical patent/EP1631235A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP04752823A 2003-05-23 2004-05-19 Compositions et methodes de modulation de l'expression de la proteine b7 Withdrawn EP1631235A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/444,206 US20040023917A1 (en) 1996-12-31 2003-05-23 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US51061403P 2003-10-10 2003-10-10
US52040103P 2003-11-13 2003-11-13
US53729104P 2004-01-16 2004-01-16
PCT/US2004/015880 WO2005000202A2 (fr) 2003-05-23 2004-05-19 Compositions et methodes de modulation de l'expression de la proteine b7

Publications (2)

Publication Number Publication Date
EP1631235A2 EP1631235A2 (fr) 2006-03-08
EP1631235A4 true EP1631235A4 (fr) 2008-05-21

Family

ID=33556628

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04752823A Withdrawn EP1631235A4 (fr) 2003-05-23 2004-05-19 Compositions et methodes de modulation de l'expression de la proteine b7

Country Status (2)

Country Link
EP (1) EP1631235A4 (fr)
WO (1) WO2005000202A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713332A4 (fr) * 2004-01-23 2010-08-18 Avi Biopharma Inc Oligomeres antisens et methodes destinees a induire la tolerance immunitaire et l'immunosuppression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074687A1 (fr) * 1999-06-04 2000-12-14 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de la proteine b7
WO2003083089A2 (fr) * 2002-03-28 2003-10-09 Revivicor Inc. Cellules tolerogenes presentant des antigenes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510319A (ja) * 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319906B1 (en) * 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2000074687A1 (fr) * 1999-06-04 2000-12-14 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de la proteine b7
WO2003083089A2 (fr) * 2002-03-28 2003-10-09 Revivicor Inc. Cellules tolerogenes presentant des antigenes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2001 (2001-02-01), QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity", Database accession no. PREV200100372589 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 August 2003 (2003-08-27), LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", Database accession no. NLM12973117 *
LIANG X ET AL: "PHENOTYPE AND ALLOSTIMULATORY FUNCTION OF DENDRITIC CELLS TREATED WITH ANTISENSE OLIGODEOXYRIBONUCLEOTIDES TARGETING CD80 OR CD86 MRNA", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 33, no. 1/02, 1 February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345 *
LIANG X ET AL: "Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345 *
LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", TRANSPLANTATION 27 AUG 2003, vol. 76, no. 4, 27 August 2003 (2003-08-27), pages 721 - 729, XP002474974, ISSN: 0041-1337 *
QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 551, XP002474973, ISSN: 0041-1345 *

Also Published As

Publication number Publication date
WO2005000202A2 (fr) 2005-01-06
WO2005000202A3 (fr) 2006-01-19
EP1631235A2 (fr) 2006-03-08

Similar Documents

Publication Publication Date Title
EP1677735A4 (fr) Methodes et compositions pour moduler la fonction des adipocytes
IL173440A0 (en) Novel formulation of ropinirole
HK1079122A1 (en) Compositions and methods for combination antiviraltherapy
IL220263A0 (en) Modulation of eif4e expression
AU2003295801A1 (en) MODULATION OF HIF1Alpha AND HIF2Alpha EXPRESSION
AU2003259735A1 (en) Small-mer compositions and methods of use
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
GB0411940D0 (en) Methods and compositions
EP1701725A4 (fr) Methodes et compositions
AU2003267644A1 (en) Dental compositions and methods
IL175509A0 (en) Methods and agents for immune modulation
AU2003256805A8 (en) Compounds compositions and methods
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003252072A8 (en) Modulation of protein kinase c-iota expression
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
EP1625141A4 (fr) Compositions a base de grp94 et procedes d'utilisation associes
GB2384705B (en) Cosmetic and related compositions
AU2003216354A8 (en) Modulators of paraptosis and related methods
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
AU2003295790A8 (en) Modulation of iap-like expression
EP1631235A4 (fr) Compositions et methodes de modulation de l'expression de la proteine b7
AU2003217392A1 (en) Methods for identifying targeting domains and methods and compositions comprising the same
EP1687398A4 (fr) Constructions d'expressions qui dependent de vih et utilisations associees
GB0327050D0 (en) Therapeutic methods compositions and uses
AU2003290763A8 (en) Modulation of jumonji expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20051219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/00 20060101ALI20060320BHEP

Ipc: C12N 5/00 20060101ALI20060320BHEP

Ipc: A61K 31/70 20060101AFI20060320BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BAKER, BRENDA F.

Inventor name: FREIER, SUSAN, M.

Inventor name: KARRAS, JAMES, G.

Inventor name: VICKERS, TIMOTHY, A.

Inventor name: BENNETT, FRANK, C.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/06 20060101ALI20080407BHEP

Ipc: A61K 48/00 20060101ALI20080407BHEP

Ipc: C12N 15/11 20060101AFI20080407BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080417

17Q First examination report despatched

Effective date: 20100324

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201